Related Funds
Fund Name | Location |
Agilent Technologies | California, Santa Clara, United States |
Bitcoin Investment Trust | New York, New York, United States |
Changrong Ziben | China, Fujian, Xiamen |
Crawley Hatfield Capital | New York, New York, United States |
Deqing Jingshi | China, Deqing, Zhejiang |
GMAG Holdings Inc. | Colorado, Denver, United States |
HH SPR-XV HK Holdings | China, Hong Kong, Hong Kong Island |
Jiangxi Guozi Chuangye Touzi Guanli | China, Guangdong, Jiangxi |
Joyceland | Beijing, Beijing, China |
K2 Wind Foundation | - |
PCS Holding AG | Frauenfeld, Switzerland, Thurgau |
Shibei Hi-Tech Park | China, Shanghai |
Smollan | Gauteng, NA - South Africa, South Africa |
TGM ventures | California, Santa Monica, United States |
Walden Venture Capital | California, San Francisco, United States |
WE Hub | Andhra Pradesh, Hyderabad, India |
Yiyixing Capital | China, Tianjin, Tianjin |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Vicebio | $100M | 23 Sep 2024 | London, England, United Kingdom | ||
Hemab | $135M | 21 Feb 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Vanqua Bio | $85M | 14 Sep 2021 | Chicago, Illinois, United States | ||
Scribe Therapeutics | $100M | 31 Mar 2021 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Vicebio | $100M | 23 Sep 2024 | London, England, United Kingdom | ||
Hemab | $135M | 21 Feb 2023 | Copenhagen, Capital Region of Denmark, Denmark | ||
Vanqua Bio | $85M | 14 Sep 2021 | Chicago, Illinois, United States | ||
Scribe Therapeutics | $100M | 31 Mar 2021 | California, United States |